ÐÄѪ¹ÜÈȵãÎÊÌâÓëר¼Ò½âÎö

ST-Segment Elevation Myocardial Infarction
Clinical perspective of optical coherence tomography and intravascular ultrasound in STEMI patients
Aspiration thrombectomy in 2015£º a TOTAL defeat?
When clinical experiences clashes against evidence based medicine£º the case of aspiration thrombectomy
in primary percutaneous coronary intervention £¨PCI£©
Therapeutic hypothermia in ST elevation myocardial infarction £¨STEMI£©£º a long way to go
Therapeutic hypothermia in ST-elevation myocardial infarction £¨STEMI£©£º targeting the appropriate STEMI
Dual antiplatelet therapy duration after drug-eluting stents£º how long?
Prolonged dual antiplatelet therapy in renal failure£º a challenging trade-off
Time for science to catch up with clinical practice?

Absorb Bioresorbable Vascular Scaffold
Bioresorbable drug eluting scaffolds¡ª¡ªare bioresorbable stents ready for today's clinical practice?
Bioresorbable vascular scaffolds in patients with acute myocardial infarction£º a new step forward
to optimized reperfusion?
Bioresorbable vascular scaffolds¡ª¡ªtime to vanish?
Overlapping meta-analyses of bioresorbable vascular scaffolds versus everolimus-eluting stents£º
bringing clarity or confusion?
Bioresorbable vascular scaffoldswhat does the future bring?
Bioresorbable scaffold¡ª¡ªthe holy grail of percutaneous coronary intervention£º fact or myth?

Percutaneous Coronary Interventions in Chronic Total Occlusion
Predictive scores in chronic total occlusions percutaneous recanalization£º only fashionable or really useful?
Scoring systems for chronic total occlusion percutaneous coronary intervention£º if you fail to prepare
you are preparing to fail
Chronic total improvement in ventricular function and survival
The impact of percutaneous coronary intervention of chronic total occlusions on left ventricular
function and clinical outcomes
Chronic total occlusion£º no more meta-analysis£¬ please¡ª¡ªa randomized clinical trial is urgently needed
Meta-analyses and randomized trials investigating percutaneous coronary intervention
of chronic total occlusions£º
what is left to explore?

Coronary In-Stent Restenosis
Five factors and three characteristics of coronary in-stent restenosis
Mechanism of in-stent restenosis after second-generation drug-eluting stents £¨DES£©£º is it different
from bare-metal stents and
first-generation DES?
Use of intravascular ultrasound vs£® optical coherence tomography for mechanism and patterns
of in-stent restenosis among bare
metal stents and drug eluting stents
In-stent restenosis and thrombosis due to metal hypersensitivity£º implications for Kounis syndrome
Contemporary drug-eluting stents and companion polymers£º durable is not synonymous with harm
Treatment of coronary in-stent restenosis¡ª¡ªevidence for universal recommendation?
Treatment for in-stent restenosis£º patient-specific decision rather than universal recommendation
In-stent restenosis£º local drug delivery with a stent or balloon?
Network meta-analyses on in-stent restenosis treatment£º dealing with complexity to clarify
efficacy and safety
Optimal interventional strategy for the treatment of coronary in-stent restenosis

Atrial Fibrillation and Left Atrial Appendage Closure
The appropriate use of risk scores in the prediction of atrial fibrillation
A meta-analysis of left atrial appendage closure for stroke prevention in atrial fibrillation¡ª¡ªadding to the
debate but elements remain unresolved
The case of stroke prevention by left atrial appendage occlusion in patients with
atrial fibrillation¡ª¡ªcan we close the file?
Left atrial appendage exclusion for atrial fibrillation£º does the protection from stroke
prevail in the long-term?
Five years of keeping a watch on the left atrial appendage¡ª¡ªhow has the WATCHMAN fared?
Percutaneous left atrial appendage closure£º here to stay

Percutaneous Left Ventricular Assist Device
High risk percutaneous coronary interventions¡ª¡ªsignificance of left ventricular assist
device for clinical practice
Percutaneous left ventricular assist device in high risk percutaneous coronary intervention
Revascularization strategy and Coronary Artery Disease
Shedding light on the gray zone
The fractional flow reserve gray zone has never been so narrow
Very long-term follow-up for left main coronary artery stenting£º a missing piece of the jigsaw puzzle
Completeness of revascularization in multivessel coronary artery disease
To complete£¬ or not to complete£¬ that is the question of revascularization in percutaneous coronary intervention
with drug-eluting stents for multivessel disease

Anti-coagulation and Pulmonary Arterial Hypertension
Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension
Registry to evaluate early and long-term disease management in PAH £¨REVEAL£©
Anti-coagulation in pulmonary arterial hypertension£º the real blood and guts

Acute Hyperglycemia and Vascular Homeostasis
Effects of acute hyperglycaemia on cardiovascular homeostasis£º does a spoonful of sugar make
the flow-mediated dilatation go down?
Hyperglycemic endothelial dysfunction£º does it happen and does it matter?
Acute hyperglycemia impairs flow-mediated dilatation through an increase in vascular
oxidative stress£ºwinter is
coming for excess sugar consumption
Aortic Regurgitation and Valvular Cardiomyopathy
Wave mice£º a new tool in the quest to characterize aortic valvular disease etiologies
Aortic regurgitation and heart valve disease in mice
Statin Therapy in Heart Failure
Statin therapy for heart failure£º to prescribe or not?
The use of statins in patients with heart failure£º more questions than answers

Hypothyroidism and Percutaneous Coronary Intervention
Major adverse cardiovascular and cerebral events in hypothyroid patients undergoing
percutaneous coronary intervention
Evidence and controversies regarding the screening for subclinical hypothyroidism in
patients with cardiovascular disease